Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Medtronic PLC pages available for free this week:
- Analysis of Short-term (Operating) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Reportable Segments
- Common Stock Valuation Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Capital Asset Pricing Model (CAPM)
- Operating Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Analysis of Revenues
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Medtronic PLC for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).
The solvency profile exhibits a period of stability between 2021 and 2024, followed by a moderate increase in leverage ratios in 2025 and a slight stabilization in 2026. While debt levels relative to equity and assets rose toward the end of the period, coverage ratios remain robust, indicating a sustained capacity to meet financial obligations.
- Leverage and Capital Structure
- Debt to equity ratios remained relatively flat between 0.46 and 0.51 from 2021 to 2024, before increasing to a peak of 0.59 in 2025. A similar pattern is observed in the debt to assets ratio, which held steady at approximately 0.27 to 0.28 for four years before rising to 0.31 in 2025. Debt to capital ratios mirrored this trend, moving from a low of 0.31 in 2022 to a peak of 0.37 in 2025. The inclusion of operating lease liabilities consistently adds a marginal increase to these metrics, typically between 0.02 and 0.03 units, without altering the overall directional trend.
- Financial Leverage
- The financial leverage ratio fluctuated within a narrow range of 1.73 to 1.81 between 2021 and 2024. An upward shift occurred in 2025, with the ratio reaching 1.91, followed by a slight correction to 1.88 in 2026. This indicates a moderate increase in the use of debt to finance assets over the total period.
- Debt Service Coverage
- Interest coverage and fixed charge coverage ratios demonstrate strong solvency, though they experienced notable volatility. Interest coverage peaked at 10.98 in 2022 before declining to 7.73 in 2024. A recovery trend followed, with the ratio climbing back to 9.58 by 2026. Fixed charge coverage followed an identical trajectory, peaking at 7.79 in 2022, dipping to 5.88 in 2024, and recovering to 7.35 by 2026. These figures suggest that earnings remain more than sufficient to cover both interest and fixed financial commitments.
Debt Ratios
Coverage Ratios
Debt to Equity
| Apr 24, 2026 | Apr 25, 2025 | Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||
| Current debt obligations | |||||||
| Long-term debt | |||||||
| Total debt | |||||||
| Shareholders’ equity | |||||||
| Solvency Ratio | |||||||
| Debt to equity1 | |||||||
| Benchmarks | |||||||
| Debt to Equity, Competitors2 | |||||||
| Abbott Laboratories | |||||||
| Elevance Health Inc. | |||||||
| Intuitive Surgical Inc. | |||||||
| UnitedHealth Group Inc. | |||||||
| Debt to Equity, Sector | |||||||
| Health Care Equipment & Services | |||||||
| Debt to Equity, Industry | |||||||
| Health Care | |||||||
Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).
1 2026 Calculation
Debt to equity = Total debt ÷ Shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The solvency profile of the entity exhibits moderate fluctuations over the analyzed six-year period, characterized by a general stability in leverage until a notable peak in 2025. The overall capital structure remains predominantly equity-funded, although a trend toward increased leverage is evident in the latter part of the period.
- Total Debt Trends
- Total debt experienced an initial decline from US$ 26,389 million in 2021 to US$ 24,114 million in 2022. Following this contraction, a steady upward trajectory was observed, culminating in a significant increase to US$ 28,516 million by April 2025. A slight reduction to US$ 27,961 million occurred in the final year of the analysis, suggesting a period of debt stabilization following the 2025 peak.
- Shareholders’ Equity Trends
- Shareholders' equity reached a peak of US$ 52,551 million in 2022 before entering a period of gradual decline. This downward trend persisted through 2025, when equity reached its lowest point at US$ 48,024 million. A partial recovery was noted in 2026, with equity increasing to US$ 49,463 million.
- Debt to Equity Ratio Analysis
- The debt to equity ratio fluctuated between 0.46 and 0.59. A period of relative stability and improvement was observed between 2021 and 2024, with the ratio moving from 0.51 to a low of 0.46 in 2022 before returning to 0.50. A significant increase to 0.59 occurred in 2025, driven by the simultaneous increase in total debt and the decrease in shareholders' equity. The ratio slightly moderated to 0.57 by 2026, reflecting the inverse movements in debt and equity during that final year.
Debt to Equity (including Operating Lease Liability)
Medtronic PLC, debt to equity (including operating lease liability) calculation, comparison to benchmarks
| Apr 24, 2026 | Apr 25, 2025 | Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||
| Current debt obligations | |||||||
| Long-term debt | |||||||
| Total debt | |||||||
| Operating lease current liability (classified in Other accrued expenses) | |||||||
| Operating lease non-current liability (classified in Other liabilities) | |||||||
| Total debt (including operating lease liability) | |||||||
| Shareholders’ equity | |||||||
| Solvency Ratio | |||||||
| Debt to equity (including operating lease liability)1 | |||||||
| Benchmarks | |||||||
| Debt to Equity (including Operating Lease Liability), Competitors2 | |||||||
| Abbott Laboratories | |||||||
| Elevance Health Inc. | |||||||
| Intuitive Surgical Inc. | |||||||
| UnitedHealth Group Inc. | |||||||
| Debt to Equity (including Operating Lease Liability), Sector | |||||||
| Health Care Equipment & Services | |||||||
| Debt to Equity (including Operating Lease Liability), Industry | |||||||
| Health Care | |||||||
Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).
1 2026 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The solvency profile over the six-year period demonstrates a fluctuating debt load and a general contraction in shareholders' equity, leading to an overall increase in financial leverage toward the latter half of the observed timeframe.
- Total Debt Dynamics
- Total debt, inclusive of operating lease liabilities, experienced an initial decrease from US$ 27,404 million in April 2021 to US$ 24,984 million in April 2022. This was followed by a consistent upward trajectory, peaking at US$ 29,626 million in April 2025, before a slight correction to US$ 29,148 million in April 2026.
- Shareholders' Equity Trends
- Shareholders' equity peaked in April 2022 at US$ 52,551 million. A period of steady decline followed, with equity falling to US$ 48,024 million by April 2025. A partial recovery occurred in the final period, with equity rising to US$ 49,463 million in April 2026.
- Debt to Equity Ratio Interpretation
- The debt to equity ratio reflects the simultaneous increase in liabilities and the erosion of the equity base. After an initial improvement to a low of 0.48 in April 2022, the ratio trended upward, reaching a maximum of 0.62 in April 2025. The final ratio of 0.59 in April 2026 indicates a higher degree of financial leverage than was present at the beginning of the period in 2021.
Debt to Capital
| Apr 24, 2026 | Apr 25, 2025 | Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||
| Current debt obligations | |||||||
| Long-term debt | |||||||
| Total debt | |||||||
| Shareholders’ equity | |||||||
| Total capital | |||||||
| Solvency Ratio | |||||||
| Debt to capital1 | |||||||
| Benchmarks | |||||||
| Debt to Capital, Competitors2 | |||||||
| Abbott Laboratories | |||||||
| Elevance Health Inc. | |||||||
| Intuitive Surgical Inc. | |||||||
| UnitedHealth Group Inc. | |||||||
| Debt to Capital, Sector | |||||||
| Health Care Equipment & Services | |||||||
| Debt to Capital, Industry | |||||||
| Health Care | |||||||
Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).
1 2026 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The solvency profile from 2021 to 2026 exhibits a period of relative stability followed by a notable increase in leverage toward the latter portion of the analyzed timeframe.
- Total Debt Dynamics
- Total debt decreased from 26,389 million US$ in 2021 to 24,114 million US$ in 2022. After this initial reduction, debt levels remained relatively stable through 2024 before experiencing a significant increase to 28,516 million US$ in 2025. A marginal contraction is observed by 2026, with debt settling at 27,961 million US$.
- Total Capital Trends
- Total capital displayed a consistent downward trend between 2021 and 2024, declining from 77,817 million US$ to 75,238 million US$. This trend reversed in 2025 and 2026, with capital increasing to 76,540 million US$ and 77,424 million US$, respectively.
- Debt to Capital Ratio Analysis
- The debt to capital ratio reached its lowest point of 0.31 in 2022. A gradual upward trajectory followed, rising to 0.33 in 2024. The ratio peaked at 0.37 in 2025, coinciding with the peak in total debt. By 2026, the ratio slightly moderated to 0.36.
The overall trend indicates a disciplined approach to solvency for the first several years, followed by a period of increased financing activity in 2025. The stabilization observed in 2026 suggests a slight moderation in the company's reliance on debt relative to its total capital base.
Debt to Capital (including Operating Lease Liability)
Medtronic PLC, debt to capital (including operating lease liability) calculation, comparison to benchmarks
| Apr 24, 2026 | Apr 25, 2025 | Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||
| Current debt obligations | |||||||
| Long-term debt | |||||||
| Total debt | |||||||
| Operating lease current liability (classified in Other accrued expenses) | |||||||
| Operating lease non-current liability (classified in Other liabilities) | |||||||
| Total debt (including operating lease liability) | |||||||
| Shareholders’ equity | |||||||
| Total capital (including operating lease liability) | |||||||
| Solvency Ratio | |||||||
| Debt to capital (including operating lease liability)1 | |||||||
| Benchmarks | |||||||
| Debt to Capital (including Operating Lease Liability), Competitors2 | |||||||
| Abbott Laboratories | |||||||
| Elevance Health Inc. | |||||||
| Intuitive Surgical Inc. | |||||||
| UnitedHealth Group Inc. | |||||||
| Debt to Capital (including Operating Lease Liability), Sector | |||||||
| Health Care Equipment & Services | |||||||
| Debt to Capital (including Operating Lease Liability), Industry | |||||||
| Health Care | |||||||
Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).
1 2026 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= ÷ =
2 Click competitor name to see calculations.
The solvency profile of the entity exhibits a period of initial deleveraging followed by a gradual increase in financial leverage over the analyzed timeframe. The relationship between total debt and total capital indicates a managed approach to capital structure, though a noticeable uptick in the debt proportion is observed in the latter years.
- Debt to Capital Ratio Trends
- The ratio experienced a decline from 0.35 in April 2021 to a low of 0.32 in April 2022. This was followed by a steady upward trajectory, peaking at 0.38 in April 2025, before settling at 0.37 by April 2026. This indicates an increased reliance on borrowed funds relative to the total capital base toward the end of the period.
- Total Debt Dynamics
- Total debt, including operating lease liabilities, showed volatility, starting at 27,404 million USD in 2021 and dropping to 24,984 million USD in 2022. A consistent increase followed, resulting in a peak of 29,626 million USD in April 2025, followed by a marginal reduction to 29,148 million USD in April 2026.
- Total Capital Stability
- Total capital remained relatively stable throughout the observed years, with a slight contraction from 78,832 million USD in 2021 to a low of 76,261 million USD in 2024. A recovery was observed in the subsequent years, returning to 78,611 million USD by April 2026. The increase in the debt-to-capital ratio was driven primarily by the rise in absolute debt levels rather than a significant contraction of the total capital base.
Debt to Assets
| Apr 24, 2026 | Apr 25, 2025 | Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||
| Current debt obligations | |||||||
| Long-term debt | |||||||
| Total debt | |||||||
| Total assets | |||||||
| Solvency Ratio | |||||||
| Debt to assets1 | |||||||
| Benchmarks | |||||||
| Debt to Assets, Competitors2 | |||||||
| Abbott Laboratories | |||||||
| Elevance Health Inc. | |||||||
| Intuitive Surgical Inc. | |||||||
| UnitedHealth Group Inc. | |||||||
| Debt to Assets, Sector | |||||||
| Health Care Equipment & Services | |||||||
| Debt to Assets, Industry | |||||||
| Health Care | |||||||
Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).
1 2026 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The solvency profile remains relatively stable over the analyzed six-year period, with a moderate increase in financial leverage observed in the latter years. While total assets and total debt exhibited some fluctuations, the overall capital structure indicates a consistent reliance on debt for approximately 27% to 31% of asset financing.
- Total Debt Trends
- Total debt experienced a period of relative stability and slight decline between April 2021 and April 2023, moving from 26,389 million USD to 24,364 million USD. However, a significant upward trajectory began in April 2024, peaking at 28,516 million USD in April 2025 before a slight reduction to 27,961 million USD in April 2026.
- Total Asset Stability
- Total assets remained remarkably consistent, fluctuating within a narrow range between 89,981 million USD and 93,083 million USD. A gradual decline was noted from 2021 through 2024, followed by a recovery phase that returned total assets to 93,028 million USD by April 2026.
- Debt to Assets Ratio Analysis
- The debt to assets ratio remained nearly flat at 0.27 to 0.28 between 2021 and 2024, suggesting a disciplined approach to leverage. A notable spike occurred in April 2025, where the ratio reached its period high of 0.31, coinciding with the peak in total debt and a simultaneous increase in assets. The ratio moderated slightly to 0.30 by April 2026, indicating a marginally higher long-term solvency risk compared to the 2021-2024 baseline.
Debt to Assets (including Operating Lease Liability)
Medtronic PLC, debt to assets (including operating lease liability) calculation, comparison to benchmarks
| Apr 24, 2026 | Apr 25, 2025 | Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||
| Current debt obligations | |||||||
| Long-term debt | |||||||
| Total debt | |||||||
| Operating lease current liability (classified in Other accrued expenses) | |||||||
| Operating lease non-current liability (classified in Other liabilities) | |||||||
| Total debt (including operating lease liability) | |||||||
| Total assets | |||||||
| Solvency Ratio | |||||||
| Debt to assets (including operating lease liability)1 | |||||||
| Benchmarks | |||||||
| Debt to Assets (including Operating Lease Liability), Competitors2 | |||||||
| Abbott Laboratories | |||||||
| Elevance Health Inc. | |||||||
| Intuitive Surgical Inc. | |||||||
| UnitedHealth Group Inc. | |||||||
| Debt to Assets (including Operating Lease Liability), Sector | |||||||
| Health Care Equipment & Services | |||||||
| Debt to Assets (including Operating Lease Liability), Industry | |||||||
| Health Care | |||||||
Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).
1 2026 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The solvency profile exhibits a period of relative stability followed by a moderate increase in leverage toward the end of the observed period. The debt-to-assets ratio fluctuated within a narrow range between 2021 and 2024 before experiencing a peak in 2025.
- Debt to Assets Ratio Trend
- The ratio moved from 0.29 in 2021 to a low of 0.27 in 2022, subsequently rising to 0.32 by 2025. A slight correction is observed in 2026, where the ratio settled at 0.31, indicating that approximately 31% of total assets are financed through debt and operating lease liabilities at the end of the period.
- Total Debt Dynamics
- Total debt, including operating lease liabilities, decreased from US$ 27,404 million in 2021 to US$ 24,984 million in 2022. This was followed by a multi-year upward trajectory, peaking at US$ 29,626 million in 2025, before a marginal decrease to US$ 29,148 million in 2026.
- Asset Base Evolution
- Total assets underwent a gradual contraction from US$ 93,083 million in 2021 to a minimum of US$ 89,981 million in 2024. A recovery phase followed, with assets increasing to US$ 91,680 million in 2025 and returning to US$ 93,028 million by 2026, effectively neutralizing the asset decline seen in the first four years.
Financial Leverage
| Apr 24, 2026 | Apr 25, 2025 | Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||
| Total assets | |||||||
| Shareholders’ equity | |||||||
| Solvency Ratio | |||||||
| Financial leverage1 | |||||||
| Benchmarks | |||||||
| Financial Leverage, Competitors2 | |||||||
| Abbott Laboratories | |||||||
| Elevance Health Inc. | |||||||
| Intuitive Surgical Inc. | |||||||
| UnitedHealth Group Inc. | |||||||
| Financial Leverage, Sector | |||||||
| Health Care Equipment & Services | |||||||
| Financial Leverage, Industry | |||||||
| Health Care | |||||||
Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).
1 2026 Calculation
Financial leverage = Total assets ÷ Shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The organization's financial leverage remained relatively stable over the analyzed period, although a notable increase in the leverage ratio occurred toward the end of the sequence. The interplay between total assets and shareholders' equity indicates a shift in the capital structure, characterized by a compression of equity relative to assets between 2022 and 2025.
- Total Asset Trends
- Total assets experienced a gradual decline from 93,083 million US$ in 2021 to a low of 89,981 million US$ in 2024. This downward trajectory reversed in the final two years, with assets increasing to 91,680 million US$ in 2025 and returning to 93,028 million US$ by 2026, effectively neutralizing the net change over the six-year window.
- Shareholders' Equity Analysis
- Shareholders' equity showed a general downward trend after an initial peak of 52,551 million US$ in 2022. Equity declined steadily for three consecutive years, reaching its lowest point of 48,024 million US$ in 2025. A moderate recovery was observed in 2026, with equity rising to 49,463 million US$.
- Financial Leverage Interpretation
- The financial leverage ratio fluctuated within a narrow range, starting at 1.81 in 2021 and dipping to a period low of 1.73 in 2022. From 2023 onward, a consistent upward trend is observed, peaking at 1.91 in 2025. This peak coincides with the lowest recorded level of shareholders' equity and a recovery in total assets, signaling an increased reliance on external financing or a reduction in the equity cushion. The ratio moderated slightly to 1.88 in 2026.
Interest Coverage
| Apr 24, 2026 | Apr 25, 2025 | Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||
| Net income attributable to Medtronic | |||||||
| Add: Net income attributable to noncontrolling interest | |||||||
| Add: Income tax expense | |||||||
| Add: Interest expense, net | |||||||
| Earnings before interest and tax (EBIT) | |||||||
| Solvency Ratio | |||||||
| Interest coverage1 | |||||||
| Benchmarks | |||||||
| Interest Coverage, Competitors2 | |||||||
| Abbott Laboratories | |||||||
| Elevance Health Inc. | |||||||
| Intuitive Surgical Inc. | |||||||
| UnitedHealth Group Inc. | |||||||
| Interest Coverage, Sector | |||||||
| Health Care Equipment & Services | |||||||
| Interest Coverage, Industry | |||||||
| Health Care | |||||||
Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).
1 2026 Calculation
Interest coverage = EBIT ÷ Interest expense
= ÷ =
2 Click competitor name to see calculations.
The analysis of interest coverage indicates a robust solvency position over the six-year period, with the company consistently maintaining a strong capacity to service its debt obligations through operating profits.
- Earnings Before Interest and Tax (EBIT)
- An overall upward trajectory is observed in operating profitability, with EBIT increasing from US$ 4,820 million in 2021 to a projected US$ 6,851 million by 2026. Despite a period of volatility between 2022 and 2024, where earnings decreased from US$ 6,070 million to US$ 5,556 million, the subsequent recovery through 2026 suggests sustained operational growth.
- Net Interest Expense
- A substantial reduction in net interest expense occurred between 2021 and 2022, dropping from US$ 925 million to US$ 553 million. Following this decline, a gradual increase was noted, peaking at US$ 729 million in 2025 before a slight moderation to US$ 715 million in 2026. The expenditure remains significantly lower than the 2021 peak.
- Interest Coverage Ratio
- The interest coverage ratio demonstrates a strong recovery and stability pattern. A sharp increase from 5.21 in 2021 to 10.98 in 2022 was driven by the combination of rising EBIT and falling interest costs. Although the ratio experienced a downward trend to 7.73 by 2024, it is projected to rise again, reaching 9.58 by 2026. This suggests a high margin of safety, as the company generates significantly more operating income than is required to cover its interest payments.
Fixed Charge Coverage
| Apr 24, 2026 | Apr 25, 2025 | Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||
| Net income attributable to Medtronic | |||||||
| Add: Net income attributable to noncontrolling interest | |||||||
| Add: Income tax expense | |||||||
| Add: Interest expense, net | |||||||
| Earnings before interest and tax (EBIT) | |||||||
| Add: Operating lease cost | |||||||
| Earnings before fixed charges and tax | |||||||
| Interest expense, net | |||||||
| Operating lease cost | |||||||
| Fixed charges | |||||||
| Solvency Ratio | |||||||
| Fixed charge coverage1 | |||||||
| Benchmarks | |||||||
| Fixed Charge Coverage, Competitors2 | |||||||
| Abbott Laboratories | |||||||
| Elevance Health Inc. | |||||||
| Intuitive Surgical Inc. | |||||||
| UnitedHealth Group Inc. | |||||||
| Fixed Charge Coverage, Sector | |||||||
| Health Care Equipment & Services | |||||||
| Fixed Charge Coverage, Industry | |||||||
| Health Care | |||||||
Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).
1 2026 Calculation
Fixed charge coverage = Earnings before fixed charges and tax ÷ Fixed charges
= ÷ =
2 Click competitor name to see calculations.
The analysis of solvency metrics indicates a strong and improving capacity to meet fixed obligations, characterized by a substantial expansion of the coverage margin after the 2021 fiscal year.
- Fixed Charge Coverage Ratio Trends
- A significant increase in the coverage ratio is observed between April 2021 and April 2022, where the ratio rose from 4.31 to 7.79. A period of moderation followed, with the ratio declining to 5.88 by April 2024. However, a renewed upward trajectory is evident in the subsequent years, with the ratio expected to reach 7.35 by April 2026, suggesting a robust long-term solvency position.
- Earnings before Fixed Charges and Tax
- An overall upward trend in earnings is observed, increasing from US$ 5,071 million in 2021 to a projected US$ 7,102 million by 2026. While a contraction occurred between 2022 and 2024, the subsequent growth in earnings has reinforced the company's ability to service its fixed costs comfortably.
- Fixed Charge Obligations
- Fixed charges saw a notable decrease from US$ 1,176 million in 2021 to US$ 813 million in 2022. Although these charges trended upward through 2024, they have since stabilized, remaining consistently around the US$ 960 million level for the 2025 and 2026 periods.